Compugen Ltd.
NASDAQ:CGENBiotechnology
+$0.01 today
- Market cap
- $191.34M
- Beta
- 2.74
- P/E (TTM)
- 5.4
- EPS (TTM)
- $0.37
Volume 0.20M
Average 0.48M
CGEN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Compugen Ltd.NASDAQ: CGEN
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $6.94M rose 20.2% year over year, ahead of the -1.0% change in trailing-twelve-month research & development. Sequentially, it rose 25.1% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.
Context
- Research & development amounted to 31.3% of revenue in FY2025, down 57.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +20.2% holds above the trailing-twelve-month pace of -1.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 22.76M USD
- Year-over-year change
- -8.3%
- 4-year CAGR
- -5.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.76M | -8.3% |
| FY2024 | 2024-12-31 | 24.81M | -28.0% |
| FY2023 | 2023-12-31 | 34.47M | +12.5% |
| FY2022 | 2022-12-31 | 30.65M | +6.8% |
| FY2021 | 2021-12-31 | 28.69M | — |
Research & Development vs competitors
How CGEN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -1.0% is the 5th highest of 9, against a peer median of +1.9%.
- Research & development amounts to 32.9% of revenue for CGEN, versus a peer median of 928.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $74.27M USD | +76.4% | +63.2% | — | |
| LTM Mar 2026 | $55.26M USD | +60.0% | -18.4% | 314.8% | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
| FY2025 | €43.62M EUR | -16.1% | -5.5% | 1565.1% | |
| LTM Mar 2026 | $31.62M USD | -19.6% | +9.2% | 6022.3% | |
| LTM Mar 2026 | $23.92M USD | -1.0% | -9.4% | 32.9% | |
| LTM Mar 2026 | $18.8M USD | -26.8% | -18.0% | 593.1% | |
| LTM Mar 2026 | $18.58M USD | +33.3% | +11.1% | — | |
| LTM Mar 2026 | $16.56M USD | +5.5% | -23.1% | 928.4% | |
| Peer median (excluding CGEN) | — | +1.9% | -6.5% | 928.4% | |
Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6M | 7.5M | 33.46M | 27.86M | 72.76M |
| Cost of Revenue | 680K | 975K | 2M | 7.93M | 9.25M |
| Gross Profit | 5.32M | 6.53M | 31.46M | 19.93M | 63.51M |
| Gross Margin | 88.7% | 87.0% | 94.0% | 71.5% | 87.3% |
| Research & Development | 28.69M | 30.65M | 34.47M | 24.81M | 22.76M |
| Selling, General & Admin | 11.7M | 11.25M | 9.98M | 10.02M | 9.43M |
| Operating Expenses | 40.39M | 41.9M | 44.45M | 34.83M | 32.19M |
| Depreciation & Amortization | 461K | 482K | 476K | 486K | 475K |
| EBITDA | (33.72M) | (33.13M) | (9.28M) | (9.19M) | 35.87M |
| EBITDA Margin | -562.0% | -441.7% | -27.7% | -33.0% | 49.3% |
| Operating Income | (35.07M) | (35.37M) | (12.99M) | (14.89M) | 31.33M |
| Operating Margin | -584.6% | -471.7% | -38.8% | -53.4% | 43.1% |
| Interest Income | 894K | 1.44M | 3.24M | 5.24M | 4.41M |
| Interest Expense | 25K | 27K | 31K | 34K | 0 |
| Other Income / Expenses | 871K | 1.74M | 3.21M | 5.18M | 4.07M |
| Income Before Tax | (34.2M) | (33.64M) | (9.78M) | (9.71M) | 35.4M |
| Pre-Tax Margin | -570.0% | -448.5% | -29.2% | -34.8% | 48.6% |
| Income Tax Expense | 0 | 58K | 8.97M | 4.52M | 54K |
| Net Income | (34.2M) | (33.69M) | (18.75M) | (14.23M) | 35.34M |
| Net Margin | -570.0% | -449.3% | -56.1% | -51.1% | 48.6% |
| EPS (Basic) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| EPS (Diluted) | (0.41) | (0.39) | (0.21) | (0.16) | 0.38 |
| Weighted Avg Shares | 84.2M | 86.56M | 87.63M | 89.53M | 93.43M |
| Weighted Avg Shares (Diluted) | 84.2M | 86.56M | 87.63M | 89.53M | 93.82M |
Compugen Ltd.
NASDAQ:CGEN
Intrinsic Alpha fair value
Locked
Current Price
$2.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.